This company specializes in the design and engineering of custom antibodies for research and therapeutic applications. They utilize advanced computational and molecular biology techniques to optimize antibody specificity and develop novel binding agents. Their services support pharmaceutical and biotechnology clients seeking high-quality antibody candidates for drug discovery pipelines.
Funding
Funding not disclosed
Founders
Product
Problem
Current influenza diagnostic tests often target internal viral proteins, leading to low sensitivity (around 50%) due to the difficulty in detecting these proteins. This can result in delayed or inaccurate diagnoses, hindering effective treatment and containment of the virus.
Solution
Antibody Design is developing a rapid, point-of-care diagnostic tool for influenza virus detection using AI neural networks and smartphone-compatible immuno-detection assays. The technology targets conserved and universally present proteins on the surface of the virus, improving detection sensitivity. By coupling quantum dot technology with digital capture, the platform aims to transform smartphones into lab-grade diagnostic readers, enabling rapid and decentralized diagnosis. The platform technology can be applied to a wide range of medical, environmental and agricultural test beds.
Target Audience
The primary target audience includes healthcare providers, diagnostic labs, and public health organizations seeking rapid and accurate influenza detection tools.
Features
- AI-powered analysis of immunoassay results
- Smartphone-based point-of-care diagnostics
- Quantum dot-coupled digital capture for enhanced signal detection
- Targets conserved surface proteins of the influenza virus
- Rapid results for timely clinical decision-making
- Potential application to medical, environmental, and agricultural testing